Consensus Core Laboratories Inc.

Equities

CLB

US21867A1051

Market Closed - Nyse Other stock markets 01:32:01 27/04/2024 am IST			5-day change	1st Jan Change
16.94 ^USD	-0.76%		-1.40%	-4.08%

25/04	Transcript : Core Laboratories Inc., Q1 2024 Earnings Call, Apr 25, 2024
24/04	Earnings Flash (CLB) CORE LABORATORIES Reports Q1 Revenue $129.6M, vs. Street Est of $124.5M	MT

Evolution of the average Target Price on Core Laboratories Inc.

Price target over the last 5 years

History of analyst recommendation changes

2e4e.gy7pTTH3rQnXeaA-xD3GDOiRXPsKOn7JtA42kKuRD-s.8EusIRyQ5EziP9VRvEq3Ob34N7gnWEeGxWxk_OnXYrvrX7wFeYPJaJ46lA~228cc64dd91c568b0127575782026569

Analyst Recommendations on Core Laboratories Inc.

Stifel Adjusts Price Target on Core Laboratories to $21 From $23, Maintains Hold Rating	29/01	MT
Citigroup Trims Price Target on Core Laboratories to $20 From $21, Maintains Sell Rating	18/23/18	MT
Piper Sandler Adjusts Core Laboratories' Price Target to $21 From $18, Keeps Neutral Rating	31/23/31	MT
Citigroup Downgrades Core Laboratories to Sell From Neutral, Trims Price Target to $21 From $22	30/23/30	MT
Morningstar Upgrades Core Laboratories to Buy From Hold, $29 Price Target	01/23/01	MT
Piper Sandler Adjusts Core Laboratories' Price Target to $19 From $18, Keeps Neutral Rating	01/23/01	MT
Stifel Adjusts Core Laboratories' Price Target to $25 From $24, Keeps Hold Rating	28/23/28	MT
BofA Downgrades Core Laboratories to Underperform From Neutral, Price Target is $21.50	18/23/18	MT
Citigroup Adjusts Price Target on Core Laboratories N.V to $26 From $21, Maintains Neutral Rating	07/23/07	MT
BofA Securities Upgrades Core Laboratories to Neutral From Underperform	09/23/09	MT
Citigroup Upgrades Core Laboratories to Neutral From Sell, Adjusts Price Target to $17 From $24	07/22/07	MT
Morgan Stanley Downgrades Core Laboratories to Underweight From Equal Weight, Keeps $20 Price Target	26/22/26	MT
Cowen Lowers Core Laboratories Price Target to $17 From $22, Maintains Market Perform Rating	02/22/02	MT
Morgan Stanley Lowers Core Laboratories' Price Target to $20 From $22, Maintains Equalweight Rating	01/22/01	MT
BofA Securities Adjusts Core Laboratories Price Target to $17 From $25, Maintains Underperform Rating	15/22/15	MT
Morgan Stanley Adjusts Core Laboratories' Price Target to $22 from $32, Keeps Equalweight Rating	13/22/13	MT
Morgan Stanley Adjusts Core Laboratories N.V 's Price Target to $22 From $32, Keeps Equalweight Rating	13/22/13	MT
Morgan Stanley Adjusts Core Laboratories' Price Target to $32 from $35, Keeps Equalweight Rating	03/22/03	MT
Piper Sandler Downgrades Core Laboratories to Underweight From Neutral	18/22/18	MT
Morgan Stanley Adjusts Core Laboratories' Price Target to $35 from $30, Keeps Equalweight Rating	11/22/11	MT
Morgan Stanley Adjusts Core Laboratories' Price Target to $30 from $32, Keeps Equalweight Rating	18/22/18	MT
Morgan Stanley Adjusts Price Target on Core Laboratories to $32 From $34, Maintains Equal-Weight Rating	07/21/07	MT
CORE LABORATORIES N : BofA Securities Downgrades Core Laboratories to Underperform from Neutral, Adjusts Price Target to $32 from $36	18/21/18	MT
CORE LABORATORIES N : Morgan Stanley Adjusts Price Target on Core Laboratories to $34 From $37, Maintains Equal-Weight Rating	11/21/11	MT
CORE LABORATORIES N : Piper Sandler Adjusts Core Laboratories' Price Target to $17.50 From $20, Maintains Neutral Rating	20/21/20	MT